ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Jan 28, 2014
Ford’s Pension Under-fundedness Under Control; Magnitude of Stock Price Multiple Discount Unwarranted Even After Considering Operational (cyclicality) and Financial (Ford Motor Credit) Risks
Ford has been a solid performer in the portfolio of the Best Ideas Newsletter. Though 2014 may not be its best year, we think the best times at the company are still ahead of it. A sub-10 trailing earnings multiple is too harsh, even after considering operational (cyclicality) and financial (Ford Motor Credit) risks.
Jan 28, 2014
5 Steps to Understand Why Apple Is Cheap; Shares Continue to Be Unfairly Weighed Down By ‘Palm Pilot’, “Moto Razr” and “Blackberry’ Memories
For Apple to be fairly valued at its after-hours price, normalized earnings per share would have to be assumed to be about $20 per annum, half of Apple’s current annual earnings of $40+ per share. We think normalized earnings at the iPad maker are much higher than what the market is giving it credit for, especially considering the promising ideas in its product pipeline. We’ve raised our fair value estimate of Apple to $680 per share thanks to the time value associated with rolling our model one year forward, offset in part by a slightly lower growth trajectory following fiscal 2014 first quarter results (ending December 28, 2013). We continue to like shares.
Jan 27, 2014
Caterpillar’s Fourth-Quarter Performance Is Better Than Feared; Free Cash Flow Significantly Improved
Caterpillar’s dealer network offers it significant competitive advantages, but mining demand trends remain abysmal.
Jan 27, 2014
Surveying Fourth Quarter Earnings at Health Care Firms
Though it may be difficult to focus on underlying equity fundamentals in the face of a volatile overall market environment, we think doing so is even more important under such circumstances. Let’s examine our thoughts on fourth-quarter earnings season in the health care space .
Jan 26, 2014
How the Grammys Can Make You a Better Investor
This concept may be the most important in all of investing history.
Jan 25, 2014
Valuentum’s Dividend Growth Portfolio Gems Shine Bright
Procter & Gamble and Microsoft put up solid performance in their respective calendar fourth quarters.
Jan 24, 2014
Starbucks’ Investors Are Forgetting That Coffee Costs Can Go Back Up; Shares Lack Valuation Support
We loved Starbucks’ fiscal first-quarter results, but shares do not consider the risk of a spike in long-term coffee prices, nor do they consider a normalizing of traffic growth trends.
Jan 24, 2014
Dividend Increases/Decreases for the Week Ending January 24
Let's take a look at dividend increases/decreases for the week ending January 24.
Jan 24, 2014
SEC Proposes Barring the Chinese Units of the Big 4 Accounting Firms for 6 Months; A Washington-Beijing Scuffle; Neither Firm-Specific, Nor Is It "New" News
Though such a topic makes for great headlines, it is neither fundamental/material to our intrinsic value estimates nor does it imply any wrongdoing by any firm. We don't view this as "new" news.
Jan 24, 2014
Icahn's In-depth Letter to Apple Still Does Not Remove Time Horizon
We believe Apple's shares have valuation upside, but as we have outlined before, activist investor Carl Icahn's proposal to force Apple to buy back stock over a certain time period ("during fiscal 2014") as opposed to under a certain price (our fair value estimate) is imprudent. We encourage Icahn to further revise his proposal. Additionally, we think Icahn's valuation process is too simplistic, and we encourage him to disclose a more rigorous valuation assessment of the firm.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.